Chardan Capital Markets Downgrades Amicus Therapeutics (FOLD) to Neutral

Chardan Capital Markets analyst Gbola Amusa downgraded Amicus Therapeutics (NASDAQ: FOLD) from Buy to Neutral with a price target of $15.00 (from $18.50).

The analyst comments "Given our conservative view on AT-GAA launch timing versus consensus expectations, we do not see it as a source of upside for Amicus in the coming 6 months. Instead, we believe the arbiter for performance for Amicus from here through end 2018 will be on how the company executes on its reiterated commitment "to build one of the most robust gene therapy pipelines in the field of rare, metabolic disorders" by "assembling a portfolio of technologies, programs and partnerships in the gene therapy space". Without visibility on what Amicus plans to do, we prefer to wait on the sidelines and therefore downgrade from Buy to Neutral, maintaining a positive bias."

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $13.46 yesterday.

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• Globe Telecom (GLO:PM) (GTMEY) PT Lowered to PHP1,930 at Macquarie
• Tokyo Tatemono Co Ltd (8804:JP) PT Raised to JPY4,480 at Nomura/Instinet